CJ CheilJedang Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CJ CheilJedang Corp.
Bracing For The Cold: Time For Korean Bioventures To Cut Down
A recent forum in South Korea heard from a venture capital executive about the changing IPO and financing environment and how bioventures might be able to cope with these changes.
Korean Firms Hunt For Overseas Biologics Manufacturers To Support Growth
Korean companies, including large conglomerates and non-biopharmas, are increasingly jumping into biologics manufacturing through cross-border acquisitions following the successes of Samsung and SK.
The Race Is On. When Will Korea Have Its Own Approved Gene Therapy?
Scrip takes a look at the landscape of the South Korean gene and cell therapy sector, which is under the spotlight with the implementation of a new cutting-edge biologics law.
Asia Deal Watch: CJ Group Continues Spree With Majority Stake Acquisition In Batavia Biosciences
Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.
- OTC, Consumer
- Other Names / Subsidiaries
- CJ HealthCare Corporation, HK inno.N Corporation
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.